Immunexpress
a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers
Immunexpress is a pioneer in the analysis of the immune system to rapidly detect sepsis. This technology uses gene expression in the blood with a specific algorithm to detect a patient’s immune response to a pathogen, rather than the traditional approach of trying to identify a causative pathogen, which represents a paradigm shift in sepsis diagnosis. The company’s mission is to develop diagnostic technologies to help clinicians and patients to fight this life-threatening disease. Immunexpress’ offices are in Seattle, Washington.
Why we invested in Immunexpress
Having worked in the anti-infective space for years, we know that sepsis is one of the biggest killers globally. Rapid diagnosis in sepsis is key to effective management of patients, and Immunexpress’ approach of measuring the host-response on a quick sample-to-result platform is a game-changer.
Discover how we can help you bring your ambition to life
Company News
-
October 6, 2020Read more
Immunexpress’ rapid test for sepsis launched in Europe on Biocartis’ Idylla platform
-
June 17, 2020Read more
Immunexpress awarded funding to develop their COVID-19 patient triage test SeptiCyte® RAPID
-
March 27, 2020Read more
Immunexpress and Biocartis to market a rapid sepsis triage test in the EU for COVID-19 patients